CJC-1295 FAQ for Laboratory Researchers
CJC-1295 is a synthetic tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH) widely evaluated in preclinical models for its extended plasma half-life and capacity to stimulate growth hormone secretion. This technical FAQ addresses core questions regarding CJC-1295 purity verification, chemical structure, reconstitution techniques, storage parameters, and comparative peptide profiles for laboratory investigations.
Quick answer
CJC-1295 is a synthetic tetrasubstituted peptide analog of growth hormone-releasing hormone (GHRH) widely evaluated in preclinical models for its extended plasma half-life and capacity to stimulate growth hormone secretion. This technical FAQ addresses core questions regarding CJC-1295 purity verification, chemical structure, reconstitution techniques, storage parameters, and comparative peptide profiles for laboratory investigations.
Key takeaways
- [CJC-1295](/research-peptides/cjc-1295-no-dac) is a synthetic 29-amino acid peptide analog derived from the truncated sequence of human growth hormone-releasing hormone (GHRH 1-29).
- The primary distinction between [CJC-1295](/research-peptides/cjc-1295-no-dac) variants lies in the addition of the Drug Affinity Complex (DAC), a bioconjugate reactive group composed of maleimidopropionic acid linked to the C-terminus via a lysine linker.
- Laboratory investigations utilize [CJC-1295](/research-peptides/cjc-1295-no-dac) to evaluate the physiological impacts of sustained versus pulsatile growth hormone elevation.
- In experimental models, [CJC-1295](/research-peptides/cjc-1295-no-dac) operates through a distinct mechanism compared to Growth Hormone Releasing Peptides (GHRPs) and ghrelin receptor agonists.
1. What Is CJC-1295 and How Does It Function as a GHRH Analog?
CJC-1295 is a synthetic 29-amino acid peptide analog derived from the truncated sequence of human growth hormone-releasing hormone (GHRH 1-29). In endogenous systems, natural GHRH consists of 44 amino acids, but the bioactivity resides within the N-terminal 29-amino acid sequence. CJC-1295 incorporates four specific amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) designed to enhance metabolic stability and resist rapid enzymatic degradation, particularly by dipeptidyl peptidase IV (DPP-IV).
When introduced into *in vitro* or *in vivo* laboratory models, CJC-1295 selectively binds to the GHRH receptor (GHRHR) located on anterior pituitary somatotropes. Activation of GHRHR triggers a G-protein-coupled signaling cascade, elevating intracellular cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA) activity. Preclinical data indicate that this pathway stimulates the transcription and pulsatile exocytosis of endogenous growth hormone (GH), which subsequently mediates hepatic production of insulin-like growth factor 1 (IGF-1). Researchers interested in broader somatotropic pathways can explore detailed mechanisms in the PX1 Research Library.
2. What Is the Structural Difference Between CJC-1295 With DAC and Without DAC?
The primary distinction between CJC-1295 variants lies in the addition of the Drug Affinity Complex (DAC), a bioconjugate reactive group composed of maleimidopropionic acid linked to the C-terminus via a lysine linker. CJC-1295 with DAC covalently binds to free thiols on circulating serum albumin (specifically Cys34) following administration in animal models. This albumin conjugation shields the peptide from renal clearance and proteolysis, extending its biological half-life from approximately 30 minutes to up to 6–8 days.
Conversely, CJC-1295 without DAC—frequently designated as Modified GRF (1-29) or Tetrasubstituted GRF 1-29—lacks the maleimido functional group. While it retains the four stabilizing amino acid substitutions that protect it against DPP-IV cleavage relative to native GHRH, it does not form covalent bonds with endogenous plasma proteins. Consequently, Modified GRF (1-29) exhibits a significantly shorter half-life (~30 minutes), eliciting acute, sharp GH peaks that closely mirror physiological GHRH pulses rather than sustained elevated baseline levels.
3. What Are the Primary In Vitro and Animal Research Applications for CJC-1295?
Laboratory investigations utilize CJC-1295 to evaluate the physiological impacts of sustained versus pulsatile growth hormone elevation. In animal models of tissue repair, preclinical studies suggest that sustained somatotropic signaling via GHRH analogs accelerates wound healing, enhances protein synthesis, and supports connective tissue integrity. These effects are primarily mediated by elevated systemic levels of IGF-1, which downregulate pro-inflammatory cytokines and upregulate collagen matrix deposition.
Additionally, CJC-1295 serves as a core tool in metabolic research. In rodent models of metabolic dysfunction and age-related body composition changes, continuous GHRH receptor stimulation has been observed to alter lipid metabolism, promoting lipolysis in adipose tissue while preserving lean muscle mass. Researchers also employ CJC-1295 in pituitary physiology studies to assess receptor desensitization kinetics, feedback regulation by somatostatin, and cross-talk between the GHRH and ghrelin receptor pathways.
4. How Does CJC-1295 Compare to Other GH Secretagogues?
In experimental models, CJC-1295 operates through a distinct mechanism compared to Growth Hormone Releasing Peptides (GHRPs) and ghrelin receptor agonists. While CJC-1295 acts directly upon the GHRH receptor to initiate cAMP-dependent GH synthesis and secretion, ghrelin mimetics such as Ipamorelin and GHRP-6 target the Growth Hormone Secretagogue Receptor (GHS-R1a), activating a phospholipase C (PLC) and intracellular calcium signal pathway.
When comparing GHRH analogs within the same structural class, CJC-1295 provides significantly greater metabolic stability than earlier generations like Sermorelin, which mirrors native GHRH 1-29 without tetrasubstitution. While Sermorelin is rapidly inactivated by DPP-IV cleavage within minutes, CJC-1295 maintains biological activity across extended windows. Researchers often analyze these interactions within broader investigations into growth hormone secretagogues to evaluate synergistic GH secretion without triggering excessive cortisol or prolactin release. Comparative studies using Tesamorelin further highlight how structural modifications alter systemic lipids and target tissue selectivity in preclinical research.
5. What Quality and Purity Standards Apply to PX1 Research CJC-1295?
PX1 Research enforces strict quality control parameters to ensure chemical integrity and lot-to-lot consistency for laboratory applications. Every batch of CJC-1295 synthesized in our USA-based, GMP-compliant facility undergoes high-performance liquid chromatography (HPLC) to verify peak purity exceeding 98%. Sequence identity and correct molecular mass are confirmed using mass spectrometry (MS) analysis, eliminating concerns regarding truncated fragments or synthetic impurities.
Because biological assays and cell culture models are highly sensitive to bacterial contaminants, PX1 subjects all peptide lots to chromogenic Limulus Amebocyte Lysate (LAL) testing to confirm low endotoxin levels (<0.1 EU/mg). Analytical testing is independently conducted by an ISO 17025 accredited laboratory, and batch-specific Certificates of Analysis (COAs) are accessible for every research account.
6. How Should CJC-1295 Lyophilized Powder Be Stored in the Laboratory?
Lyophilized CJC-1295 powder exhibits robust stability when stored under controlled environment conditions. For short-term storage (under 30 days), the unopened vial may be held at 2°C to 8°C. For long-term preservation (up to 24 months), the peptide should be kept desiccanter-protected at -20°C or -80°C to minimize hydrolytic degradation and oxidation of sensitive amino acid residues.
Repeated freeze-thaw cycles must be strictly avoided, as thermal fluctuations disrupt the physical matrix of the lyophilized cake and accelerate peptide aggregation. Upon receipt, research facilities should store vials away from direct light exposure in a dedicated laboratory freezer equipped with continuous temperature monitoring.
7. What Are the Standard Reconstitution Guidelines for CJC-1295?
Reconstitution protocols must adhere to aseptic laboratory techniques inside a laminar flow hood. The recommended solvent for reconstituting CJC-1295 depends on the intended experimental timeframe. Bacteriostatic water (0.9% benzyl alcohol) is preferred for multi-use laboratory protocols requiring storage over several weeks, as the preservative prevents microbial proliferation. For single-use or sensitive cell culture assays, sterile 0.9% sodium chloride or sterile water for injection (WFI) should be utilized.
When introducing solvent into the vial, direct the stream slowly down the glass wall rather than directly onto the lyophilized cake. Gently swirl the vial in a circular motion until the peptide fully dissolves into a clear, colorless solution. Never agitate or vortex the vial vigorously, as mechanical shear stress can induce peptide denaturation or irreversible aggregation.
8. How Should Reconstituted CJC-1295 Solutions Be Handled and Stored?
Once reconstituted, CJC-1295 solution is substantially less stable than its lyophilized form. Reconstituted vials should be kept refrigerated at 2°C to 8°C and protected from light. When prepared with bacteriostatic water, liquid aliquots maintain chemical stability for up to 28 days under refrigeration. If dissolved in unpreserved sterile water or saline, the solution must be used immediately or discarded within 24 hours.
For long-term usage of reconstituted stock solutions, researchers may prepare single-use aliquots using polypropylene or low-protein-binding microcentrifuge tubes and store them at -20°C. Refreezing previously thawed liquid peptide solutions is not recommended due to degradation risks.
9. How Can Institutional Researchers Order CJC-1295 from PX1 Research?
PX1 Research caters directly to academic institutions, biotechnology firms, and qualified contract research organizations (CROs). Orders placed Monday through Friday ship same-day from our primary fulfillment centers in California and Arizona, ensuring rapid transit times and reduced environmental exposure during transport.
Principal investigators and procurement officers seeking bulk quantities, custom vial configurations, or recurring inventory allocations can register through the PX1 wholesale program. Qualified institutional accounts receive dedicated support, lot reservation capabilities, and direct access to comprehensive analytical documentation.
Frequently Asked Questions
What is the primary chemical function of CJC-1295?
CJC-1295 functions as a synthetic growth hormone-releasing hormone (GHRH) analog that binds to pituitary GHRH receptors to stimulate endogenous growth hormone synthesis and secretion in preclinical models.
What is the molecular weight and formula of CJC-1295 with DAC?
CJC-1295 with DAC has a chemical formula of C152H252N44O42 and a target molecular weight of approximately 3647.28 Da, inclusive of the tetrasubstituted modified GRF (1-29) backbone and the maleimidopropionic acid linker.
Why is CJC-1295 synthesized with tetrasubstitution?
The four amino acid substitutions (D-Ala2, Gln8, Ala15, and Leu27) protect the peptide against rapid cleavage by the dipeptidyl peptidase IV (DPP-IV) enzyme, significantly increasing its metabolic half-life compared to native GHRH.
How does the Drug Affinity Complex (DAC) extend the half-life of CJC-1295?
The DAC moiety contains a maleimide group that forms a stable, covalent bond with the Cys34 amino acid residue of circulating serum albumin, preventing rapid renal filtration and enzymatic degradation.
What purity level is guaranteed for PX1 Research CJC-1295?
Every lot of CJC-1295 supplied by PX1 Research is verified by HPLC to possess a minimum purity of 98%, accompanied by mass spectrometry sequence confirmation.
What solvents are suitable for reconstituting CJC-1295 for lab research?
Bacteriostatic water (0.9% benzyl alcohol) is recommended for multi-dose experimental protocols stored at 2–8°C. Sterile 0.9% sodium chloride or sterile water for injection may be used for immediate single-use assays.
Are PX1 peptides tested for endotoxins?
Yes, all PX1 research peptides undergo LAL assay testing to confirm endotoxin levels fall strictly below 0.1 EU/mg, ensuring suitability for sensitive in vitro and animal models.
Where can researchers obtain the Certificate of Analysis (COA) for CJC-1295?
Lot-specific COAs generated by an independent ISO 17025 accredited testing facility are available for download directly on the PX1 Research website or by contacting support with the batch lot number.
Can CJC-1295 be combined with GHRPs in research protocols?
Preclinical literature frequently documents co-administration protocols combining GHRH analogs (like CJC-1295) with ghrelin receptor mimetics (like Ipamorelin) to evaluate synergistic growth hormone release across distinct receptor pathways.
What is the shipping origin and speed for PX1 peptide orders?
PX1 Research ships all orders directly from facilities in California and Arizona, offering same-day dispatch for orders placed Monday through Friday before cut-off times.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.